Pharming Group NV (PHARM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pharming Group NV (PHARM) has a cash flow conversion efficiency ratio of 0.121x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€32.03 Million ≈ $37.44 Million USD) by net assets (€264.64 Million ≈ $309.40 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PHARM market cap overview for the company's overall valuation and market capitalisation.
Pharming Group NV - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Pharming Group NV's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Pharming Group NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pharming Group NV ranked by their cash flow conversion efficiency. Explore Pharming Group NV (PHARM) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China CYTS Tours Holding Co Ltd
SHG:600138
|
0.044x |
|
Plato Income Maximiser Ltd
AU:PL8
|
0.027x |
|
Controladora Vuela Compañía de Aviación S.A.B. de C.V
MX:VOLARA
|
4.000x |
|
Annexon Inc
NASDAQ:ANNX
|
-0.258x |
|
Zhejiang Xinzhonggang Thermal Power Co Ltd
SHG:605162
|
0.045x |
|
Scanfil Oyj
HE:SCANFL
|
0.025x |
|
Shanghai Zhongzhou Special Alloy Materials Co. Ltd.
SHE:300963
|
-0.045x |
|
Ton Yi Industrial Corp
TW:9907
|
0.042x |
Annual Cash Flow Conversion Efficiency for Pharming Group NV (2005–2024)
The table below shows the annual cash flow conversion efficiency of Pharming Group NV from 2005 to 2024. View Pharming Group NV (PHARM) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €214.16 Million ≈ $250.38 Million |
€-1.79 Million ≈ $-2.10 Million |
-0.008x | +91.51% |
| 2023-12-31 | €198.05 Million ≈ $231.55 Million |
€-19.55 Million ≈ $-22.85 Million |
-0.099x | -188.20% |
| 2022-12-31 | €204.64 Million ≈ $239.24 Million |
€22.90 Million ≈ $26.77 Million |
0.112x | -40.31% |
| 2021-12-31 | €192.72 Million ≈ $225.31 Million |
€36.13 Million ≈ $42.23 Million |
0.187x | -62.14% |
| 2020-12-31 | €183.73 Million ≈ $214.80 Million |
€90.98 Million ≈ $106.36 Million |
0.495x | -22.12% |
| 2019-12-31 | €117.26 Million ≈ $137.09 Million |
€74.56 Million ≈ $87.16 Million |
0.636x | -2.76% |
| 2018-12-31 | €70.64 Million ≈ $82.58 Million |
€46.19 Million ≈ $54.00 Million |
0.654x | -67.83% |
| 2017-12-31 | €22.56 Million ≈ $26.37 Million |
€45.84 Million ≈ $53.60 Million |
2.032x | +658.01% |
| 2016-12-31 | €28.89 Million ≈ $33.77 Million |
€-10.52 Million ≈ $-12.30 Million |
-0.364x | +47.13% |
| 2015-12-31 | €26.06 Million ≈ $30.47 Million |
€-17.95 Million ≈ $-20.99 Million |
-0.689x | -289.43% |
| 2014-12-31 | €36.29 Million ≈ $42.43 Million |
€-6.42 Million ≈ $-7.50 Million |
-0.177x | +89.31% |
| 2013-12-31 | €6.92 Million ≈ $8.09 Million |
€-11.45 Million ≈ $-13.39 Million |
-1.655x | -223.33% |
| 2012-12-31 | €-10.12 Million ≈ $-11.83 Million |
€-13.58 Million ≈ $-15.88 Million |
1.342x | -89.84% |
| 2011-12-31 | €-1.54 Million ≈ $-1.80 Million |
€-20.34 Million ≈ $-23.78 Million |
13.210x | +2676.91% |
| 2010-12-31 | €13.43 Million ≈ $15.70 Million |
€-6.89 Million ≈ $-8.05 Million |
-0.513x | +64.11% |
| 2009-12-31 | €19.07 Million ≈ $22.30 Million |
€-27.24 Million ≈ $-31.85 Million |
-1.428x | -75.31% |
| 2008-12-31 | €17.45 Million ≈ $20.40 Million |
€-14.21 Million ≈ $-16.62 Million |
-0.815x | -30.04% |
| 2007-12-31 | €50.58 Million ≈ $59.13 Million |
€-31.69 Million ≈ $-37.05 Million |
-0.626x | -59.15% |
| 2006-12-31 | €65.78 Million ≈ $76.91 Million |
€-25.89 Million ≈ $-30.27 Million |
-0.394x | +12.20% |
| 2005-12-31 | €34.04 Million ≈ $39.79 Million |
€-15.26 Million ≈ $-17.84 Million |
-0.448x | -- |
About Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more